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ORIGINAL ARTICLE / ÖZGÜN ARAŞTIRMA 
Prevalence of thyroid disorders and the correlation of thyroid profile with liver 
enzymes, serum activin-A and follistatin during the treatment of patients with chronic 
hepatitis C genotype 1 and 4
Kronik hepatit C genotip 1 ve 4 hastaların tedavisi sırasında tiroid bozuklukları prevalansı ve 
tiroid profili ile karaciğer enzimleri, serum activin-A ve follistatin arasındaki ilişki
Ahmed Mohammed Ashshi1, Adel Galal El-Shemi1,3, Adnan AlZanbagi2, Bassem Refaat1
ÖZET
Amaç:  Kronik  hepatit  C  (KHC)  ve  Peg-interferon-  alfa 
(Peg-INF-α)  serum  aktivinleri  ve  follistatini  düzenler  ve 
tiroid hastalıkları (TH) ile birliktedir. Bu çalışmanın amacı 
KHC’nin indüklediği TH sıklığını belirlemek ve karaciğer 
hasarı, serum activin-A ve follistatin’in tiroid fonksiyonları 
ve tiroid otoantikorları ile ilişkisini araştırmaktır.
Yöntemler: Bu çalışma kesitsel olup, 3 gruba ayrılan 132 
KHC’li hastadan serumları alınmıştır: Tedavisiz 56 hasta, 
24 haftalık Peg-INF-α tedavisi almış 30 hasta ve Peg-
INF-α  tedavisi  tamamlanmış  46  hasta.  Tiroid  stimülan 
hormon (TSH), serbest tiroksin (FT4) ve tiroid otoantikor-
ları, serum activin-A ve follistatin düzeyleri ELISA yönte-
miyle ölçüldü.
Bulgular: Hastaların %15’inde (n=20) tiroid hastalığı sap-
tandı, bunların çoğunluğu (%80) otoimmün tiroidit olup, 
kadınlarda daha sık (%70) idi. TSH reseptör antikorları 
(TSHR-Abs), diğer antikorlardan anlamlı yüksek bulundu 
(p<0,05) ve 24 haftalık tedavi grubunda anlamlı artmıştı 
(p<0,05). TSH ve FT4 karaciğer enzimleri ile anlamlı kö-
rele idi (p<0,05). Tiroid hastalığı olanlarla ötiroid olanlar 
arasında activin-A ve follistatin değerleri bakımından an-
lamlı fark yoktu (p>0,05). Ancak TSHR-Abs ile follistatin, 
activin-A ve activi/follistatin oranı arasında anlamlı kore-
lasyonlar saptandı (p<0,05) .
Sonuç: Hastalarımızda KHC ve/veya Peg-INF-α’nın in-
düklediği tiroid bozuklukları yaygın olup, bunların çoğu 
otoimmundur ve kadınlarda daha sık idi. İlaveten, activin-A 
ve/veya  follistatin  TSHR-Abs  oluşumu/agrevasyonunda 
etkili olabilir. Sonuçlarımızı doğrulamak ve KHC’daki tiroid 
hastalıkları oluşum mekanizmalarını açıklamak için ilave 
çalışmalara gereksinim vardır.
Anahtar kelimeler: Kronik hepatit C, tiroid hastalığı, acti-
vin-A, follistatin, Suudi Arabistan
ABSTRACT
Objectives Chronic hepatitis C (CHC) and peg-interferon-α 
(Peg-INF-α) modulate serum activins and follistatin and are 
associated with thyroid disorders (TD).The aim of this study 
was to determine the frequency of CHC induced TD and to 
investigate the correlation of liver damage, serum activin-A 
and follistatin with the thyroid function parameters and thy-
roid autoantibodies. 
Methods: The study was cross-sectional and sera were ob-
tained from 132 patients with CHC who were divided into 3 
groups: 56 patients with no treatment, 30 after 24 weeks of 
Peg-INF-α and 46 at the end of 48 weeks Peg-INF-α. Thy-
roid stimulating hormone (TSH), free thyroxin (FT4), thyroid 
antibodies (Tabs), serum activin-A and follistatin levels were 
measured using ELISA. 
Results: Thyroid disorders were detected in 15% (n=20), 
more frequent in females (70%) and the majority were auto-
immune thyroiditis (80%). TSH receptor antibodies (TSHR-
Abs) were significantly prevalent compared to the other anti-
bodies (p<0.05) and significantly increased in the 24 weeks 
group (p<0.05). TSH and FT4 correlated significantly with 
liver enzymes (p<0.05). There was no significant difference 
in activin-A and follistatin values between thyroid disorder 
and euthyroids. However, significant correlations were found 
between TSHR-Abs  concentration  with  follistatin,  activin-A 
and activin/follistatin ratio (p<0.05). 
Conclusion: Thyroid disorders induced by CHC and/or Peg-
INF-α were common in our patients, more prevalent in fe-
males and the majority are autoimmune. Additionally, activin-
A and/or follistatin could be involved in the induction/aggra-
vation of TSHR-Abs. Further studies are needed to confirm 
our findings and to explore the mechanisms by which CHC 
induces thyroid disorders. J Clin Exp Invest 2014; 5 (3): 343-
353
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INTRODUCTION
The treatment of chronic hepatitis C infection (CHC) 
is currently based on a combination of pegylated 
interferon-α (Peg-INF- α) and ribavirin and the treat-
ment duration depends on the viral genotype [1]. 
One of the most prevalent CHC and Peg-INF-α ex-
trahepatic disorders is thyroid dysfunction [2]. Types 
of thyroid disorders (TD) associated with HCV and 
Peg-INF-α  based  therapy  range  from  subclinical 
to overt hypo- and hyperthyroidism due to autoim-
mune and non-autoimmune predisposition [3]. The 
prevalence of HCV and Peg-INF-α induced thyroid-
itis ranges between 2.5% to 35% [4,5]. 
The most common form of thyroid autoimmu-
nity during CHC is the presence of thyroid antibod-
ies  (Tabs)  without  clinical  disease  [6]. Antibodies 
include  thyroid  peroxidase  antibodies  (TPO-Abs), 
TSH  receptor  antibodies  (TSHR-Abs)  and  thyro-
globulin antibodies (TG-Abs); and patients may be 
positive for one or more of these antibodies [3,7,8]. 
However, about 50% of patients who develop thy-
roid dysfunction during Peg-IFN-α therapy do not 
develop Tabs, suggesting that thyroid dysfunction 
could also be mediated by a direct effect on thyroid 
cell function rather than immune mediated mecha-
nism [9]. IFN induced non-autoimmune thyroiditis 
exists in two forms, destructive thyroiditis and hy-
pothyroidism [3].
Activins are cytokines that belong to the trans-
forming growth factor-β superfamily and follistatin is 
the main regulator of the local bioactivity of activ-
ins since binding of activins to follistatin is almost 
irreversible [10]. Activins are involved in the patho-
genesis  of  inflammatory  and  autoimmune  human 
diseases [11,12]. Activin-A can have both pro- and 
anti-inflammatory actions depending on both cellu-
lar and temporal contexts [12].
Activins are secreted in the cytoplasm of the 
thyroid follicle cells [13,14], indicating an active syn-
thesis and it has been suggested that they are in-
volved in the stimulation of DNA synthesis and pro-
liferation of thyrocytes of porcine thyroid cells in vivo 
[15]. The expression of activins’ intracellular media-
tors (Smad) have also been reported in thyroid cells 
and in the nucleus of thyroid tumour cells, indicating 
propagation of activin signalling in thyrocytes [16].
Additionally, a slight increase in activin-A was 
associated with hyperthyroidism [17]. While a sig-
nificant increase of activin-A was associated with 
hypothyroidism [18]. The evidence that immunos-
taining for activin A in thyroid follicular cells is more 
intense  in  patients  with  Graves’  disease  than  in 
normal subjects [19]. Serum levels of activin-A are 
higher in goitrous patients with autoimmune thyroid-
itis more than control subjects [18]. 
Currently, there is no report from Saudi Arabia 
or  other Arabian  Gulf  countries  about  the  preva-
lence of thyroiditis in CHC patients with or without 
treatment with Peg-INF-α based therapy. Addition-
ally,  we  have  previously  reported  that  CHC  and 
Peg-INF-α based therapy modulate the serum con-
centrations of activin-A and follistatin [20,21]. The 
present study was therefore conducted to measure 
the frequency and types of thyroid disorders associ-
ated with CHC and/or its therapy in treatment naïve 
Saudi patients diagnosed with HCV genotype 1 and 
4. We also measured the correlation between liver 
damage, serum activin-A, follistatin and activin/fol-
listatin ratio with the thyroid function parameters at 
the time of diagnosis, after 24 weeks of treatment 
initiation and at the end of the treatment protocol of 
48 weeks. 
METHODS
Ethical approval
The study was approved by the institutional review 
board and ethics committee of King Abdullah Medi-
cal City (IRB 12-028). All samples were collected 
following obtaining informed written consent from all 
the participants. 
Study design
This was a cross-sectional study. Serum samples 
were collected from 132 Saudi patients diagnosed 
with CHC genotype 1 or 4 and for whom positive 
polymerase chain reaction following reverse tran-
scription was positive for HCV RNA according to the 
principle inclusion and exclusion criteria (table 1). 
The patients were divided according to the timing of 
the samples into 3 groups:
A.  No  treatment  group  (NT):  This  group  in-
cluded 56 patients according to the inclusion and 
exclusion criteria and who did not start their treat-
ment protocol. The patients consisted of 24 males 
and 32 females with age range (22-70 years). Thirty 
two cases were positive for viral genotype 4 and 24 
for genotype 1.
B. 24 weeks group (24W): This group consist-
ed of samples collected from 30 patients who had 
Peg-INF-α based therapy for 24 weeks. The group 
included 20 males and 10 females with age range of 
(21-64 years). Sixteen cases were genotype 4 and 
14 genotype 1.Ashshi AM, et al. Thyroid disorders, thyroid profile, serum activin-A and follistatin in chronic hepatitis C 345
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Table 1. Principles inclusion and exclusion criteria
Principal inclusion criteria Principle exclusion criteria
Patient age ≥ 18 years. Patient age < 18 years.
HCV RNA positive Previous non-responders/relapse
No concurrent infection with HBV or HIV Solid organ transplant (renal, heart, or liver, etc.)
Dual therapy using peg-INF-α 2a or 2b with ribavirin Mono- or triple based therapy
Treatment naïve patients Autoimmune condition (type 1 DM, rheumatoid arthritis, etc.)
Compensated liver disease (e.g. no liver cirrhosis, fail-
ure or cancer) & APRI ≤ 1.2 History or current thyroid disease
Acceptable hematological and biochemical indices Uncontrolled type 2 DM and HTN
No or controlled type 2 DM and hypertension Concurrent chronic disease (Renal failure, CHD, etc.)
DM: Diabetes mellitus, HTN: Hypertension, CHD: Coronary heart disease
C. End of treatment group (ET): The final group 
included samples collected from 46 patients at the 
end of a 48 weeks treatment protocol. The patients 
were 24 males and 22 females with age range (19-
61 years). Genotype 4 and 1 were positive in 28 and 
18 cases, respectively.
All  treated  patients  received  PEG-INF-α-2a 
(Pegasys, Roche, Basel, Switzerland) at a dosage 
of 180 µg per week in combination with daily dose 
of ribavirin (Copegus, Roche) based on the body 
weight (1000 mg if < 75 kg or 1200 mg if ≥ 75 kg).
The results of liver function parameters and vi-
ral load at the time of sample collection were per-
formed as part of the routine laboratory follow-up. 
The study measured the prevalence of thyroid 
disorders and the different types of thyroid antibod-
ies in all groups. We also measured concentrations 
of activin-A and follistatin in all samples and positive 
samples  for  the  different  thyroid  antibodies  were 
compared to the negative samples within the same 
group. Furthermore, serum TSH and free T4 were 
measured  in  all  samples  and  correlation  studies 
were conducted with the different thyroid antibod-
ies, liver enzymes, activin-A and follistatin. 
Calculation of APRI
APRI was calculated using the following equation: 
(AST/upper limit of normal)/platelet count (X 109/L) 
X 100. The interpretation of the APRI results was 
performed according to previously published stud-
ies [20,21]. All samples were collected following the 
calculation of their APRI and only samples with ≤ 
1.2 were included into the study to avoid samples 
collected from patients suffering from liver cirrhosis.
Measurement of TSH and free T4
The quantitative measurement of thyroid stimulating 
hormone (TSH) and free thyroxin hormone (FT4) 
was done using electro-chemiluminescence immu-
noassay (ECLIA) on Cobas e411 (Roche Diagnos-
tics International Ltd, Switzerland) according to the 
manufacturer protocol. The reference range accord-
ing to the manufacturer for TSH and free T4 was 
0.27−4.20 µIU/mL and 12-22 pmol/L, respectively. 
The detection sensitivity was 0.005 µIU/mL for TSH 
and 0.3 pmol/L for FT4. The intra- and interassay 
coefficients of variations for FT4 were 1.7 and 3.9% 
and for TSH were 1.4% and 3.4%, respectively. The 
diagnosis  and  classification  of  thyroid  abnormali-
ties were according to the guidelines of the National 
Academy of Clinical Biochemistry (NACB) for labo-
ratory diagnosis and monitoring of thyroid diseases 
[22]. Hypothyroidism was considered when TSH > 
4.5 µIU/mL and the level of FT4 defined the type as 
either primary (FT4 < 12 pmol/L) or subclinical (FT4 
≥ 12 pmol/L). Hyperthyroidism was considered for 
TSH < 0.10 µIU/mL and FT4 > 22 pmol/L.
Measurement of thyroid autoantibodies
ELISA  was  used  to  detect  the  IgG  antibodies 
against TSH receptor (TSHR-abs), TPO (TOP-abs) 
and TG (TG-abs) (Human Diagnostica, Germany) 
by following the manufacturer’s instructions and the 
optical density of the plates was measured within 10 
min using a plate reader at 450 nm. The cut-off val-
ues according to the manufacturer’s instructions for 
a positive test for TSHR-abs was > 1.5 IU/l, nega-
tive was < 1 IU/l and equivocal was between 1.1-1.5 
IU/l. Results for TPO antibodies were considered 
negative if < 80 WHO-IU/ml, equivocal between 80-Ashshi AM, et al. Thyroid disorders, thyroid profile, serum activin-A and follistatin in chronic hepatitis C 346
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150 WHO-IU/ml and positive if > 150 WHO-IU/ml. 
For TG antibodies, results were considered nega-
tive if < 80 WHO-IU/ml, equivocal if between 80-200 
WHO-IU/ml and positive if > 200 WHO-IU/ml.
The  IMTEC-TSH  Receptor-Antibodies  ELISA 
has a sensitivity of 100% and a specificity > 95%. 
The kit has a lower detection limit of 0.21 IU/L and 
the inter-assay and intra-assay imprecision is CV 
10.9 – 12.9 % and CV 2.2 – 7.1 %, respectively. 
The  IMTEC-TPO-Antibodies  has  a  sensitivity  of 
92.9% and a specificity of 97.6%, and the analytical 
sensitivity of the kit is ≤ 3.0 WHO-IU/ml. The inter-
assay and intra-assay imprecision is CV 11.1% and 
CV 8.9%, respectively. The IMTEC-TG-Antibodies 
ELISA kit has a sensitivity of 92.8% and a specificity 
of 97.9%, and the analytical sensitivity of the kit is 
≤ 6.0 WHO-IU/ml. The inter-assay and intra-assay 
imprecision is CV 8.2% and CV 8.3%, respectively.
Measurement of human activin-A and 
follistatin serum concentrations
ELISA was used for quantitative measurement of 
human activin-A and follistatin in all samples (R&D 
systems, USA) as previously described. As report-
ed by the manufacturer, the lowest detection limit of 
activin-A by the used kit is 3.7 pg/mL and the upper 
limit is 1500 pg/mL. The intra-assay and inter-assay 
precisions of the kit are 4.3% and 5.8%, respec-
tively. The kit cross reacts by 0.2% and 0.45% with 
inhibin-A  and  activin-AB,  respectively. The  detec-
tion range of the follistatin kit is 250-16000 pg/mL 
and the minimum detectable dose is 83 pg/mL. The 
intra-assay and inter-assay precisions are <3% and 
<9%,  respectively.  Activin-A/follistatin  ratio  index 
(AFRI) was calculated as follow: [Activin-A/follistatin 
x 100].
Statistical analysis
Statistical  analysis  of  the  results  was  performed 
using SPSS version 20. The Chi square (X2) test 
was used for frequency analysis. According to data 
normality, either student’s T test or Mann-Whitney U 
test was used to compare between 2 groups. Fur-
thermore, one way ANOVA followed by Tukey post 
hoc test or Kruskal–Wallis followed by Dunn’s post 
hoc test were used to compare between more than 
2 groups depending on the data homogeneity. Cor-
relations were determined using Pearson’s test. P 
value < 0.05 was considered significant.
RESULTS
Demographic results and general laboratory 
parameters
There  was  no  significant  difference  in  the  mean 
age, the distribution of gender, viral genotype and 
viral load at diagnosis, liver enzymes and thyroid 
hormones either between the three study groups or 
within each group (table 2).
Table 2. Demographic and laboratory characteristics of all study participants according to the different study groups
No treatment 
(n = 56)
24 weeks 
(n = 30)
End of treatment
(n = 46)
Age (years) 50.1 ± 16.3 46.4 ±13.3 44.1 ± 14.6
Gender
Male 46.4%  66.7%  39%
Female 53.6%  33.3%  61%
Genotype
G1 43% 46.7% 50%
G4 57% 53.3% 50%
Viral Load at diagnosis (IU/mL) 1125694 ± 555544 999187 ± 400348 1048288 ± 303944
Albumin (g/dL) 3.8 ± 0.47 4.06 ± 0.22 4.06 ± 0.42
ALP (IU/L) 116 ± 55.6 79.4 ± 39.1 93.7 ± 51.6
ALT (IU/L) 45.5 ± 19.9 43.2 ± 25.6 34.8 ± 23.7
AST (IU/L) 47 ± 18.6 38.8 ± 17.8 33.4 ± 15.4
APRI 0.68 ± 0.37 0.59 ± 0.31 0.64 ± 0.35
TSH (µIU/L) 2.4 ± 1.1 2.7 ± 1.5 3 ± 2.1
FT4 (pmol/L) 14.2 ± 3.3 14 ± 3.8 13.4 ± 3.8Ashshi AM, et al. Thyroid disorders, thyroid profile, serum activin-A and follistatin in chronic hepatitis C 347
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Prevalence and types of thyroiditis in the 
different study groups
Thyroid disorder was detected in 20 patients (15%) 
of the study participants. Six cases were found in the 
‘No treatment’ group, 8 patients in the ‘24W group’ 
and 6 in the ‘End of treatment’ group. Regarding 
gender, 70% of thyroiditis was observed in females 
(n = 14) and 30% in males (n = 6) with female: male 
ratio 2.3:1. Half of the patients (n = 10, 50%) had 
subclinical thyroiditis and the remainder had clinical 
thyroiditis. The prevalence of hypothyroidism and 
hyperthyroidism  was  60%  vs.  40%,  respectively 
(Figure 1). Sixteen patients had autoimmune thy-
roiditis (80%) and four had non-autoimmune thyroid 
disease (20%) (Figure 2).
Figure 1. The prevalence of thyroiditis (A) in all study participants, (B) in male and female participants (C) according to 
hypo- or hyperthyroidism and (D) according to clinical and subclinical presentation
Prevalence of thyroid antibodies in the 
different study groups
The three thyroid antibodies were detected in all 
groups except for the ‘No treatment group’ in which 
all cases were negative for TPO antibodies (Figure 
3). The total number of positive cases in the 3 groups 
for  TSHR-Abs  (n  =  64,  48.4%)  was  significantly 
higher when compared with the other 2 antibodies 
(P = 0.1X10-4) (Figure 3). Furthermore, there was 
no significant difference (P = 0.4) between the num-
ber of positive cases for antibodies against TPO (n 
= 6, 4.5%) when compared to TG (n = 16, 12.1%).
TSHR-Abs were detected in the ‘NT’ (n = 20, 
35.7%),  ‘24W’  (n  =  22,  73.3%)  and  ‘ET’  (n  =22, 
47.8%)  groups.  There  was  a  significant  increase 
in the prevalence of TSHR-Abs following treatment 
with Peg-INF-α for 24 weeks (P = 0.02) followed by 
a non-significant decline at the end of the 48 weeks 
treatment protocol. However, there was no signifi-
cant difference in the number of positive cases be-
tween the ‘NT’ vs. ‘ET’ groups and the ‘24W’ vs. ‘ET’ 
groups (P > 0.05) (Figure 3).
Serum  concentrations  of  TSHR-Abs  showed 
a similar pattern to the prevalence as a significant 
increase was detected between the ‘24W’ (4.25 ± 
1.08 IU/mL) and ‘NT’ groups (2.1 ± 0.36 IU/mL) (P 
= 0.0004). Additionally, a significant difference was 
observed between the ‘24W’ and ‘ET’ (2.3 ± 0.49 IU/Ashshi AM, et al. Thyroid disorders, thyroid profile, serum activin-A and follistatin in chronic hepatitis C 348
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mL) groups (P =0.001). There was no significant dif-
ference between the ‘NT’ and ‘ET’ groups (P = 0.4) 
(Figure 3). Furthermore, a significant increase in the 
concentration of TSHR-Abs was observed in the au-
toimmune thyroiditis (3.88 ± 0.43 IU/mL) compared 
to the positive cases for TSHR-Abs in the euthyroid 
group (2.1 ± 0.25 IU/mL) (P = 0.003) (Figure 3).
Figure 2. The prevalence of thyroiditis in the 132 study participants and the prevalence in the ‘No treatment’ group 
(NT), ’24 weeks’ group (24W) and the ‘End of Treatment’ group (ET) according to auto- and non-autoimmune
Figure 3. Prevalence of (A) thyroid autoantibodies in all study participants, (B) different thyroid autoantibodies accord-
ing to study groups, (C) TSHR-Abs according to study groups (a = p < 0.05 compared to NT group) and (D) mean ± SD 
of serum TSHR-Abs concentrations in the positive cases in each study group (a = p < 0.05 compared to NT group and 
b = p < 0.05 compared to 24W group).Ashshi AM, et al. Thyroid disorders, thyroid profile, serum activin-A and follistatin in chronic hepatitis C 349
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Figure 4. Correlation of ALT (A & B), AST (C & D), ALP (E & F) and ASPRI (G & H) with TSH (left column) and free T4 
(Right column)Ashshi AM, et al. Thyroid disorders, thyroid profile, serum activin-A and follistatin in chronic hepatitis C 350
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Correlation between liver enzymes and 
thyroid hormones
Liver  enzymes  and  APRI  correlated  significantly 
with TSH and free T4 (Figure 4). ALT significantly 
correlated with TSH (r = 0.332, P = 0.004) and in-
versely with free T4 (r = -0.371, P = 0.002). Addition-
ally, a similar significant pattern of correlation, was 
observed for AST with TSH (r = 0.277, P = 0.02) and 
free T4 (r = -0.265, P = 0.03). The strongest sig-
nificant correlation with thyroid hormones was ob-
served with APRI (r = 0.355, P = 0.004; r = -0.505, 
P = 0.00002) for TSH and free T4, respectively. ALP 
did not correlate with neither TSH (r = 0.046, P = 
0.7) nor free T4 (r = 0.11, P = 0.3) (Figure 4). 
Activin-A and follistatin in hepatitis C induced 
thyroiditis
There  was  no  significant  difference  in  serum  ac-
tivin-A, follistatin and activin/follistatin ratio (A/F) be-
tween autoimmune thyroiditis and euthyroid cases 
(Table 3) and between positive and negative cases 
for TSHR-Abs within each study groups (P > 0.05) 
(Table 4). 
There  was  a  significant  negative  correlation 
between serum activin-A and TSHR-Abs concentra-
tion (r = -0.206, P = 0.01). Furthermore, a significant 
positive  correlation  for  TSHR-Abs  concentration 
with follistatin (r = 0.303, P = 0.0001) and a signifi-
cant inverted correlation with A/F ratio (r = -0.342, P 
= 0.0005) was observed (Table 5).
Table 3. Mean of activin-A, follistatin and AFRI ratio ± SD in autoimmune thyroiditis (AT) and euthyroidism (EU) within 
each of the study group. No significant difference was observed between positive and negative cases within each 
group.
NT group 24W group ET group
EU AT EU AT EU AT
Activin-A (pg/mL) 864.2 ± 233 822.8 ± 163 424 ± 193 382.7 ± 107 471.7 ± 127.1 695.5 ± 227.1
Follistatin (pg/mL) 473.9 ± 201.5 408.6 ± 265.6 807.8 ± 285 644 ± 105.9 684.9 ± 362.2 425.8 ± 187.1
AFRI  195 ± 71 248 ± 87 77 ± 27 61 ± 22 118 ± 31 170 ± 74
Table 4. Mean of activin-A, follistatin and AFRI ± SD in positive (+) and negative (-) cases of TSHR-Abs within each of 
the study group. No significant difference was observed between positive and negative cases within each group.
NT group 6MT group ET Group
- TSHR-Abs + TSHR-Abs - TSHR-Abs + TSHR-Abs - TSHR-Abs + TSHR-Abs
Activin-A (pg/mL) 830.8 ± 348.6 929.1 ± 248.8 508 ± 232 479 ± 174.7 540.5 ± 189.3 478 ± 120
Follistatin (pg/mL) 451.4 ± 193.6 507.6 ± 202.8 1076.8 ± 382 850.5 ± 277.6 674.8 ± 211.5 761.2 ± 227.2
AFRI 194 ± 68 207 ± 81 59 ± 30 78 ± 32 149 ± 81 105 ± 42
Table 5. Results of correlation analysis using Pearson’s test for serum activin-A, follistatin and AFRI with TSH, FT4, 
TSHR-Abs, TPO-Abs and TG-Abs
TSH FT4 TSHR-Abs TPO-Abs TG-Abs
Activin-A r  0.023 -0.064 -0.206* 0.027 0.089
p  0.7 0.4 0.01 0.7 0.3
Follistatin r  -0.091 -0.053 0.304* -0.086 0.005
p  0.7 0.5 0.0002 0.3 0.9
AFRI r 0.019 0.062 -0.342* 0.079 0.007
p 0.8 0.4 0.00001 0.3 0.9Ashshi AM, et al. Thyroid disorders, thyroid profile, serum activin-A and follistatin in chronic hepatitis C 351
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DISCUSSION
The current research is the first to report the preva-
lence and types of thyroid disorders associated with 
CHC infection with or without Peg-INF-α therapy in 
treatment naïve Saudi patients. Furthermore, this is 
the first study to report significant correlations be-
tween serum concentrations of TSH receptor anti-
bodies with serum Follistatin, activin-A and activin-
A/follistatin ratio. However, there was no significant 
difference in serum concentrations of activin-A and 
follistatin between positive and negative cases for 
TSH receptor antibodies. Our results suggest that 
activin-A and/or follistatin may play a role in the de-
velopment of TSH receptor antibodies. Finally, sig-
nificant  correlations  between ALT, AST  and APRI 
were also observed with the levels of serum TSH 
and T4, suggesting that liver damage following CHC 
is associated with hypothyroidism. 
There are several drawbacks in our study. A 
limitation of our study is that it presents data from 
a  small  sample  size  and  increasing  the  number 
of patients would increase the statistical power of 
the study to reflect the actual prevalence of CHC 
and Peg-INF-α induced thyroid diseases in Saudi 
patients. However, we were able to detect thyroid 
disorders in 15% and TSH receptors antibodies in 
48.4% of the study population, suggesting that thy-
roid disorders are a common complication of CHC 
and its currently used treatment in Saudi patients. 
A further limitation is that we did not measure 
free T3, total T3 and total T4 to appropriately evalu-
ate the thyroid functions. Nevertheless, the routine 
screening  and  clinical  biochemical  diagnosis  of 
thyroid disorders are essentially based on measur-
ing TSH and free T4. Another limitation is that we 
adopted a cross-sectional design and performing a 
longitudinal prospective study would reveal the ac-
curate timing of thyroiditis development and would 
allow proper follow-up for patients to determine the 
prognosis and rate of recovery. 
The  reported  prevalence  of  HCV  and  Peg-
INF-α  induced  thyroiditis  in  developed  countries 
ranges between 2.5% to 35% [23]. Currently there 
are only two available reports from the Middle East 
and the prevalence ranged between 8.5 and 20% 
[24,25]. Females are at higher risk of developing 
thyroiditis  following  CHC  and  peg-INF-α  [3].  Fur-
thermore, hypothyroidism has also been reported 
to be more common than hyperthyroidism [26,27]. 
Similar results were also reported form the UK[28], 
Taiwan [29] and Australia [30]. Our study supports 
the previous findings as it showed an overall 15% 
prevalence of CHC and peg-INF-α induced thyroid 
disorders in Saudi patients, the majority were fe-
males and 60% of the patients had hypothyroidism. 
Thyroid  autoimmunity  are  significantly  more 
common  with  CHC,  which  is  associated  with  the 
development of the different types of thyroid auto-
antibodies (Tabs) [31]. Patients infected with HCV 
present 40-42% of detectable Tabs levels; whereas 
in patients with hepatitis B virus, the index varies 
from 5 to 10%[31]. Our results correlate with the 
previous studies as we have detected Tabs in 60% 
of our patients. However, the higher prevalence in 
our study could be due to differences in the study 
design and the sample size, which is smaller in our 
study, or different environmental and genetic predis-
positions [27].
The  most  commonly  studied  and  associated 
Tabs with HCV and peg-INF-α induced thyroiditis in 
the literature are TPO and TG antibodies [3]. How-
ever, patients with destructive thyroiditis were also 
reported to have inhibitory TSHR-Abs[32]. The most 
prevalent Tabs in our study were TSHR-Abs and the 
lowest were TPO-Abs. Additionally, TPO-Abs were 
only detected during the course of therapy and at 
the end of treatment, suggesting a role for INF-α 
based therapy in their synthesis. 
The differences between our findings and the 
previous reports could be due to the non-longitudi-
nal design of our study and the small sample size, 
which may have underestimated the prevalence of 
TPO and TG antibodies. This variability can also 
be attributed to the diverse genetic predisposition 
of the subjects [27,33]. However, the detected sig-
nificant difference in the prevalence of TSHR-Abs 
in our study suggests that the development of anti-
bodies against TSH receptor are common in Saudi 
patients during CHC and during the treatment with 
Peg-INF-α based therapy.
Strong correlations between liver damage and 
thyroid disorders have been reported [34]. Non-al-
coholic fatty liver diseases and abnormal liver en-
zymes are significantly associated with hypothyroid-
ism and the the prevalence of liver diseases and 
enzymes increase steadily with increasing grades 
of hypothyroidism [34]. Furthermore, a decrease in 
serum T3 concentration and T3:T4 ratio is frequent-
ly observed in patients with liver cirrhosis probably 
due to impaired conversion of T4 to T3 in the liver 
[35]. Thyrotoxicosis is also associated with a vari-
ety of abnormalities of liver function [36] and results 
from  a  recent  study  suggests  that  low  FT4  con-
centrations  are  associated  with  hepatic  steatosis Ashshi AM, et al. Thyroid disorders, thyroid profile, serum activin-A and follistatin in chronic hepatitis C 352
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[37]. Serum TSH level was also significantly higher 
in nonalcoholic fatty liver diseases and it has also 
been suggested that measurement of FT3 and FT4 
levels may all be useful as predictors of mortality in 
intensive care patients who have cirrhosis [38]. Our 
findigns are in agreement with the previous stud-
ies as they showed significant correlations between 
AST and ALT with both TSH and FT4 in patients with 
CHC and the strongest correlation was observed for 
thyroid hormones with APRI.
APRI is used as a predictor of liver fibrosis and 
cirrhosis in CHC as a replacement of liver biopsy 
in a substantial proportion of patients [39]. Several 
studies  have  confirmed  the  significant  correlation 
between APRI and both the stage of liver fibrosis 
and the grade of activity [21]. Therefore, we sug-
gest that the degree of liver damaged associated 
with CHC could be responsible for the non autoim-
mune thyroid abnormalities. However, investigating 
the prevalence of thyroid disorders associated with 
different stages of liver fibrosis and cirrhosis due to 
CHC is required to support our hypothesis.
Harada et al. confirmed that pathological ex-
pression of activin-A was associated with hyperthy-
roidism [17], while a significant increase of activin-A 
was associated with hypothyroidism and serum lev-
els of activin-A were higher in goitrous patients with 
autoimmune thyroiditis[18]. The present work dis-
agrees with the previous observations as it showed 
no  significant  difference  in  the  concentrations  of 
activin-A between autoimmune thyroiditis and eu-
thyroid cases within each study groups. Similar re-
sults were also observed for follistatin and activin/
follistatin ratio (A/F). The non-significant difference 
could be due the small sample size included in the 
study. However, the current study is the first to re-
port that serum concentration of TSHR-Abs signi-
fantly correlates positively with serum follistatin and 
negatively with activin-A and A/F ratio. 
Activin-A has been established as a main regu-
lator of immune responses [20,21] and pathologi-
cal activin-A levels have been associated several 
autoimmune diseases such as rheumatic diseases 
[40], systemic lupus erythematosus [41] and aller-
gic airway diseases [42]. Therefore, we suggest that 
activin-A and/or follistatin are involved in HCV and 
Peg-INF-α induced autoimmune thyroiditis.
In  conclusion,  thyroid  disorders  induced  by 
HCV and peg-INF-α treatment are common in Sau-
di patients, with higher prevalence in females and 
the majority is autoimmune in nature. Additionally, 
activin-A and/or follistatin could be involved in the 
induction/agrevation  of TSH receptors antibodies. 
Further studies are needed to confirm the detected 
prevalence of thyroid disorders in our study and to 
explore the role of activins and their binding protein 
in hepatitis C induced thyroiditis.
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